ArticleJournal of global health2026
Associations of plasma proteomic and polygenic profiling with incident psoriasis risk: a prospective cohort study.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a common chronic immune-mediated disease with substantial systemic and public health burden, yet early molecular signatures associated with its onset remain insufficiently characterised. Although both circulating proteins and genetic susceptibility may contribute to psoriasis development, their prospective and joint associations with incident psoriasis remain unclear. We aimed to evaluate the individual and combined effects of proteomic and polygenic profiling on psoriasis risk. Methods: We identified psoriasis-related protein signature using plasma proteomic data (2919 proteins) from 39 377 individuals in the UK Biobank. We prioritised eight biomarkers to formulate protein risk scores (ProSs) and computed polygenic risk scores (PRSs) using 62 single-nucleotide polymorphisms (SNPs). Then, we used Cox proportional hazards models to evaluate association of ProS and PRS with psoriasis risk, and performed stratified and sensitivity to explore the robustness of our findings. Results: A total of 479 incident psoriasis cases occurred over a median follow-up of 13.60 years (interquartile range = 12.89-14.31). The hazard ratios (HRs) for psoriasis were 1.40 (95% confidence interval (CI) = 1.08-1.80) and 2.72 (95% CI = 2.17-3.42) in the medium and high ProS groups, respectively, vs. the low ProS group (P-value for trend <0.001). When considering genetic susceptibility, participants with a high PRS and a high ProS had a greater risk of incident psoriasis (HR = 4.25; 95% CI = 2.97-6.07) compared to those with a low PRS and low ProS, as well as a greater 10-year absolute risk (25.99 per 1000 individuals). They also had a relative excess risk of 2.16 (95% CI = 0.98-3.35) due to additive interaction, accounting for 49% (95% CI = 29%-69%) of the psoriasis incidence. In the high genetic risk group, compared with individuals with low ProS, those with high ProS had an excess risk of 18.45 (95% CI = 17.90-18.98) cases per 1000 individuals over 10 years. Conclusions: Integrating the proteomic and polygenic tools could help improve the precision of psoriasis risk classification and facilitate the identification of high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.